{
    "clinical_study": {
        "@rank": "97324", 
        "arm_group": {
            "arm_group_label": "Risk-adapted postremission treatment.", 
            "arm_group_type": "Other", 
            "description": "Ara-C, G-CSF, Autologous peripheral blood stem cell transplantation, Allogeneic matched related or unrelated donor transplant, G-CSF Priming, CD34+ selection, Myeloablative or reduced intensity conditioning, Mylotarg purging before autologous PBSC transplantation."
        }, 
        "brief_summary": {
            "textblock": "The AML-03 regimen investigates the addition of G-CSF priming to both induction and\n      consolidation chemotherapies administrated in the previous AML-99 trial (NCT01716793)\n      refines risk-stratification based on biological characterization also the AML-03 trial\n      incorporates novel approaches for hematopoietic stem cell transplantation: such as Mylotarg\u2122\n      \"in vivo purging\" in autografts, extends unrelated volunteers donors for allotransplants in\n      high-risk patients, and introduces reduced intensity conditioning in patients with elder age\n      (more than 50 years old).\n\n      The aims of these modifications are to analyse eficacy and toxicity of this induction and\n      consolidation therapy and to analyse the disease free survival in patients who achieved\n      complete response following a risk adjusted therapy."
        }, 
        "brief_title": "Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Leukemia, Myelocytic, Acute", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Neoplasm, Residual"
            ]
        }, 
        "detailed_description": {
            "textblock": "Induction chemotherapy: idarubicin (12mg/m2/day intravenous, days 1, 3 and 5),\n      intermediate-dose cytarabine (500mg/m2/12h, intravenous, days 1, 3 and 5) and etoposide\n      (100mg/m2/day, intravenous, from day 1 to 3) as in AML-99 trial  (NCT01716793), with the\n      addition of subcutaneous G-CSF from day 0 to the last day of chemotherapy. This induction\n      therapy is repeated if complete remission (CR) is not achieved after the first course of\n      treatment.\n\n      Consolidation therapy (as in AML-99 trial): mitoxantrone (12mg/m2/day, intravenous, days 4\n      to 6) and intermediate-dose cytarabine (500mg/m2/12h from day 1 to 6).\n\n      Risk-stratification according to cytogenetics, courses to CR and availability of an\n      HLA-identical sibling:\n\n        -  Patients in the favorable cytogenetics group [t(8;21), inv(16) or t(16;16)] and\n           Leukocyte index <20 at diagnosis (LI=white blood cell count (WBC) x (blasts in bone\n           marrow/100) are treated with one course of high-dose cytarabine (3g/m2/12h,\n           intravenous, days 1, 3 and 5), but in case of LI>20 at diagnosis the intention is to\n           perform an autologous peripheral blood stem cell (PBSC) transplantation.\n\n        -  Patients in intermediate risk group, with normal karyotype, a single course of\n           induction chemotherapy to achieve the CR, the absence of adverse molecular features\n           (FLT3-ITD or MLL-PTD) and low minimal residual disease levels after consolidation\n           (MRD<0,1%) receive an autologous PBSC transplant, regardless of having an HLA-identical\n           sibling.\n\n        -  The remaining patients defined as high-risk patients are treated with an allogeneic\n           stem cell transplantation. Depending on the age, if the patient has an HLA-identical\n           sibling donor, up to age of 50 years old it is performed with conventional conditioning\n           therapy and positive selection of CD34+, older patients receive a reduced intensity\n           conditioning regimen.\n\n        -  Very high risk patients without a sibling are allocated to unrelated donor (9-10/10).\n           Patients with adverse cytogenetics and/or FLT3-ITD without an adequate donor received\n           Mylotarg\u2122 as \"in vivo purging\" followed by an autologous PBSC transplantation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with newly diagnosed AML, classified using OMS criteria.\n\n          -  Patients with 70 years old or younger.\n\n        Exclusion Criteria:\n\n          -  Patients previously treated for the AML with chemotherapy different from hidroxiurea.\n\n          -  Acute promyelocytic leukemia with t(15;17).\n\n          -  Cronic mieloid leukemia in blastic crisis.\n\n          -  Leukemias that appear after other myeloproliferative processes.\n\n          -  Leukemias that survive after myelodysplasic syndromes of more than 6 months of\n             evolution.\n\n          -  Presence of other neoplasic disease in activity.\n\n          -  Secondary AML which appears after cured malignant disease (for instance, Hodgking\n             disease), and those who are still exposed to alkilant agents or radiation.\n\n          -  Abnormal renal and hepatic functions with creatinin and/or bilirrubine 2 times higher\n             than the normal threshold, except when the alteration should be attributed to the\n             leukemia.\n\n          -  Patient with an ejection fraction below 40%, symptomatic cardiac deficiency or both.\n\n          -  Patients with neurological or concomitant psychiatric disease.\n\n          -  Positivity by HIV."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "862", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723657", 
            "org_study_id": "AML-03"
        }, 
        "intervention": [
            {
                "arm_group_label": "Risk-adapted postremission treatment.", 
                "description": "Intermediate dose during induction phase to remission.\nHigh dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20.", 
                "intervention_name": "Ara-C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Risk-adapted postremission treatment.", 
                "description": "In patients with favorable cytogenetics with a Leukocyte index above 20.\nPatients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor.", 
                "intervention_name": "Autologous peripheral blood stem cell transplantation.", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Risk-adapted postremission treatment.", 
                "description": "-Patients without favorable/intermediate characteristics.", 
                "intervention_name": "Allogeneic matched related or unrelated donor transplant.", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Risk-adapted postremission treatment.", 
                "description": "Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.\nAdministration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L.", 
                "intervention_name": "G-CSF", 
                "intervention_type": "Drug", 
                "other_name": "Filgastrim."
            }, 
            {
                "arm_group_label": "Risk-adapted postremission treatment.", 
                "description": "-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.", 
                "intervention_name": "CD34+ selection.", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Risk-adapted postremission treatment.", 
                "description": "Patients without favorable/intermediate characteristics and without matched related donor.", 
                "intervention_name": "Mylotarg purging before autologous PBSC transplantation", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Gemtuzumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Leukemia", 
            "Myeloid", 
            "Acute", 
            "Young", 
            "CETLAM"
        ], 
        "lastchanged_date": "November 6, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08916"
                    }, 
                    "name": "Hospital Universitari Germans Trias i Pujol"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L'Hospitalet del Llobregat", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08907"
                    }, 
                    "name": "ICO Hospital Universitari de Bellvitge"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "A Coru\u00f1a", 
                        "country": "Spain", 
                        "state": "Coru\u00f1a", 
                        "zip": "15006"
                    }, 
                    "name": "Hospital A Coru\u00f1a"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain", 
                        "state": "Mallorca", 
                        "zip": "07198"
                    }, 
                    "name": "Hospital Universitari Son Espases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain", 
                        "state": "Mallorca"
                    }, 
                    "name": "Hospital Universitari Son Dureta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tortosa", 
                        "country": "Spain", 
                        "state": "Tarragona", 
                        "zip": "43517"
                    }, 
                    "name": "Hospital Verge de la Cinta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08003"
                    }, 
                    "name": "Hospital del Mar"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Vall d'Hebron"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Cl\u00ednic de Barcelona"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08022"
                    }, 
                    "name": "Centro Medico Teknon"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Hospital de la Santa Creu i Sant Pau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Girona", 
                        "country": "Spain", 
                        "zip": "17007"
                    }, 
                    "name": "Hopital Universitari de Girona Dr. Josep Trueta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lleida", 
                        "country": "Spain", 
                        "zip": "25006"
                    }, 
                    "name": "Hospital Universitari Arnau de Vilanova"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }, 
                    "name": "Hospital Universitario La Paz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malaga", 
                        "country": "Spain", 
                        "zip": "29010"
                    }, 
                    "name": "Hospital Universitario Virgen de la Victoria"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murcia", 
                        "country": "Spain", 
                        "zip": "30008"
                    }, 
                    "name": "Hospital General Universitario de Murcia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41014"
                    }, 
                    "name": "Hospital Universitario Virgen del Rocio"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarragona", 
                        "country": "Spain", 
                        "zip": "43007"
                    }, 
                    "name": "Hospital Universitari Joan XXIII"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Terrassa", 
                        "country": "Spain", 
                        "zip": "08225"
                    }, 
                    "name": "Mutua de Terrassa"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46010"
                    }, 
                    "name": "Hospital Clinico Universitario de Valencia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valladolid", 
                        "country": "Spain", 
                        "zip": "41010"
                    }, 
                    "name": "Hospital Universitario Rio Hortega"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Risk Adapted Treatment for Primary AML in Adults, Based on Genetics and Minimal Residual Disease (MRD) in Patients up to the Age of 70 Years.", 
        "overall_official": [
            {
                "affiliation": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", 
                "last_name": "Jorge Sierra, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", 
                "last_name": "Salut Brunet, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Departament de Salut de la Generalitat de Catalunya", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Analyze the efficacy and toxicity of IDICE-G (idarubicin, intermediate doses of ara-C and etoposide) and G-CSF to achieve complete remission.", 
                "measure": "Complete remission rate (CRR)", 
                "safety_issue": "Yes", 
                "time_frame": "2 months."
            }, 
            {
                "description": "Analyze the disease free suvival of patients in remission, with a therapeutic strategy adjusted to the prognostic factors.\nMortality in remission after chemotherapy and/or peripheral blood stem cell tranplantation.", 
                "measure": "Disease free survival (DFS).", 
                "safety_issue": "No", 
                "time_frame": "4 years."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723657"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Toxicity of the induction and intensification treatment in patients with more than 60 years old, in terms of unexpected adverse drug reaction, morbidity and mortality.", 
                "measure": "Toxicity in patients over 60 years old.", 
                "safety_issue": "Yes", 
                "time_frame": "4 years."
            }, 
            {
                "description": "Study the immunophenotype characteristics and/or molecular markers at diagnosis, and during the different treatment phases.", 
                "measure": "Evaluation of minimal residual disease (MRD) by flow cytometry and/or molecular markers during and after treatment.", 
                "safety_issue": "No", 
                "time_frame": "4 years."
            }, 
            {
                "description": "Study the effect of post-remission treatments in patients with more than 60 years to evaluate the success of consolidation treatments.", 
                "measure": "Feasibility of post-remission treatment in patients with 60 or more years old.", 
                "safety_issue": "No", 
                "time_frame": "4 years."
            }
        ], 
        "source": "Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2003", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}